Nuvelo Initiates Phase 2 Trial Of RNAPc2 In Patients With Metastatic Colorectal Cancer

Sat, 06 Jan 2007 02:00 PM EST

... Nuvelo, Inc. (Nasdaq: NUVO) today announced that patient enrollment has begun in a Phase 2 trial of recombinant nematode anticoagulant protein c2 (rNAPc2) for the treatment of metastatic colorectal carcinoma (mCRC), the second leading cause of cancer-related death in the United States. [click link for full article] ...